TrialSignal transduction and targeted therapy2021

Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).

Rong Tao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.